NVG 300
Alternative Names: NVG-300Latest Information Update: 09 Oct 2024
At a glance
- Originator NervGen Pharma
- Class Antidementias; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Spinal cord injuries; Stroke
- Research Alzheimer's disease; Multiple sclerosis